Extended Data Fig. 1: Pathway analysis based on the differential transcriptome of tumor vascular endothelium in TLS-rich tumors. | Nature Immunology

Extended Data Fig. 1: Pathway analysis based on the differential transcriptome of tumor vascular endothelium in TLS-rich tumors.

From: Simultaneous STING and lymphotoxin-β receptor activation induces B cell responses in tertiary lymphoid structures to potentiate antitumor immunity

Extended Data Fig. 1

A previous transcriptome analysis of human breast adenocarcinoma vasculature identified differentially expressed genes between non-HEV endothelium of TLS-rich vs. TLS-free tumors34. a, Volcano plot presentation of differentially expressed genes. The log2 fold change of gene expression in the endothelium of TLS-rich tumors compared with TLS-free tumors is shown on the X-axis. P values are shown on the Y-axis (-log10). The genes with statistically significant differences are shown in red dots. p < 0.05. b, An upstream prediction analysis of these gene sets was performed using the Ingenuity Pathway Analysis (IPA) program. This study identified Type-I IFN, tumor necrosis factor (TNF), Toll-like receptor 7 (TLR7), TLR9, and lymphotoxin-β (LTβ) suggesting inflammation and innate immunity signaling in the tumor microenvironment. Also identified were CXCL13, CD40L, IL21, and IL21R, which regulate B cell recruitment, activation, and differentiation as well as generation/maintenance of follicular helper T (TFH) cells and germinal center development.

Back to article page